
[Federal Register Volume 76, Number 146 (Friday, July 29, 2011)]
[Notices]
[Pages 45578-45579]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-19067]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0002]


Request for Nominations for Members on a Public Advisory 
Committee; Medical Imaging Drugs Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting 
nominations for 12 members to serve on the Medical Imaging Drugs 
Advisory Committee in the Center for Drug Evaluation and Research.
    FDA has a special interest in ensuring that women, minority groups, 
and individuals with physical disabilities are adequately represented 
on advisory committees and, therefore, extends particular encouragement 
to nominations for appropriately qualified female, minority, or 
physically challenged candidates. Final selection from each vacancy 
will be determined by the expertise required to meet specific Agency 
needs and in a manner to ensure appropriate balance on membership.

[[Page 45579]]


DATES: Nominations should be received before September 27, 2011.

ADDRESSES: All nominations for membership, except for consumer-
nominated members and industry representatives members, should be sent 
to Minh Doan (see FOR FURTHER INFORMATION CONTACT).

FOR FURTHER INFORMATION CONTACT:
Minh Doan, Center for Drug Evaluation and Research, Food and Drug 
Administration, Bldg. 31, rm. 2417, 10903 New Hampshire Ave., Silver 
Spring, MD 20993-0002, 301-796-9001, Fax: 301-847-8533, E-mail: 
MIDAC@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting 
members on the Medical Imaging Drugs Advisory Committee (the 
Committee). (Elsewhere in this issue of the Federal Register is a final 
rule adding the Medical Imaging Drugs Advisory Committee to the list of 
FDA standing advisory committees in 21 CFR 14.100 as well as a request 
for nominations of nonvoting industry representatives, and a request 
for nominations of voting and nonvoting consumer representatives.)

I. Function

    The Committee advises the Commissioner of Food and Drugs or 
designee in discharging responsibilities as they relate to helping to 
ensure safe and effective drugs for human use and, as required, any 
other product for which FDA has regulatory responsibility. The 
Committee also reviews and evaluates data concerning the safety and 
effectiveness of marketed and investigational human drug products for 
use in diagnostic and therapeutic procedures using radioactive 
pharmaceuticals and contrast media used in diagnostic radiology.

II. Criteria for Members

    Persons nominated for membership on the Committee must have 
adequately diversified research and/or clinical experience appropriate 
to the work of the committee in such fields as nuclear medicine, 
radiology, epidemiology or statistics, and related specialties.
    The specialized training and experience necessary to qualify the 
nominee as an expert suitable for appointment is subject to review, but 
may include experience in medical practice, teaching, research, and/or 
public service relevant to the field of activity of the committee. The 
term of office is up to 4 years.

III. Nomination Procedure

    Any interested person may nominate one or more qualified persons 
for membership on the Committee. Self-nominations are also accepted. 
Nominations must include a current, complete resume or curriculum vitae 
for each nominee, current business and/or home address, telephone 
number, and e-mail address if available. Nominations must specify the 
advisory committee for which the nominee is recommended. Nominations 
must also acknowledge that the nominee is aware of the nomination, 
unless self-nominated. Potential candidates will be required to provide 
detailed information concerning such matters as financial holdings, 
employment, and research grants and/or contracts to permit evaluation 
of possible sources of conflicts of interest.
    This document is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: July 22, 2011.
David Dorsey,
Acting Deputy Commissioner for Policy, Planning and Budget.
[FR Doc. 2011-19067 Filed 7-28-11; 8:45 am]
BILLING CODE 4160-01-P


